GlyGenix Therapeutics

GlyGenix Therapeutics, Inc. is focused on treating and curing Glycogen Storage Disease Type 1a which is a heritable gene mutation that results in altered metabolic homeostasis. Our expertise in the application of UltraSound-mediated Plasmid DNA delivery (USP) will be unique and will provide a safe in vivo delivery approach for targeting the normal gene to the appropriate tissue. The product opportunities target unmet clinical needs and are expected to represent a significant therapeutic advance. GlyGenix Therapeutics, Inc.'s mission is focused on the development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen Storage Disease Type 1a.